Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P27487

UPID:
DPP4_HUMAN

ALTERNATIVE NAMES:
ADABP; Adenosine deaminase complexing protein 2; Dipeptidyl peptidase IV; T-cell activation antigen CD26; TP103

ALTERNATIVE UPACC:
P27487; Q53TN1

BACKGROUND:
Dipeptidyl peptidase 4, known for its aliases such as ADABP and CD26, is integral to T-cell mediated immune responses and cellular proliferation. It serves as a receptor for human coronavirus MERS-CoV-2, highlighting its significance in microbial infection. The protein's ability to bind and activate various molecules underscores its pivotal role in immune system regulation and cellular communication.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Dipeptidyl peptidase 4 offers a promising avenue for therapeutic intervention. Its critical involvement in immune system activation and potential role as a receptor for pathogens like MERS-CoV-2 underscores its value as a target for drug discovery, aiming to enhance immune responses or prevent viral entry.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.